Canaccord Adams downgrades AtriCure, Inc. (Nasdaq: ATRC) from Buy to Hold. Price target $7.

Canaccord analyst says, "The DOJ ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE